PubMed چکیده/رکورد

Syringic Acid-Loaded Emulsomes as a Neuroprotective Delivery System: Formulation Optimization and In-Vivo Pharmacokinetic Evaluation.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Syringic acid (SA) demonstrates significant anti-inflammatory, antioxidant, and neuroprotective properties. Unfortunately, its clinical applicability is limited by low solubility and low bioavailability. SA-loaded emulsomes were developed to overcome these limitations. The emulsomes were prepared using thin-film hydration method and optimized by a Central Composite Design. Three independent variables were studied: the solid lipid-to-phosphatidylcholine ratio, drug amount, and solid lipid type (trilaurin or tripalmitin). The measured responses were entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP). The optimized formula exhibited an EE% of 61.92 ± 0.09%, a PS of 190.02 ± 0.13 nm, a PDI of 0.21 ± 0.07 and a ZP of -36.3 ± 0.98 mV. In-vitro release studies demonstrated a sustained release profile, with 92% of SA released over 24 h. The relative bioavailability of SA from the optimized formula was 219% compared to the unformulated drug. A physiologically based pharmacokinetic (PBPK) model was developed to predict plasma and tissue distribution. The model predicted a twofold increase in brain bioavailability, suggesting the potential for improved brain penetration and retention. These findings establish emulsomes as a promising nanoplatform for overcoming syringic acid's biopharmaceutical barriers and advancing its clinical potential.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

central composite designemulsomessyringic acidtrilaurintripalmitin
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Formulation, evaluation and characterization of fexofenadine IR and paracetamol SR multiparticulate drug delivery system.

BACKGROUND: Multiparticulate Drug Delivery (MDD) system are particularly considered as well suited systems for controlling oral preparations that have low risk of dose-dumping. OBJECTIVES: The current research work was aimed to prepare Fexofenadine HCl immediate release (IR) and Paracetamol sustained release (SR) pellets in a single dosage unit for the treatment of Allergic Rhinitis. Extrusion-spheronization was used to fabricate pelle…

PubMed2026

PGR expression as a pharmacogenomic companion biomarker to GENE70-derived genomic risk in ER-positive/HER2-negative breast cancer.

BACKGROUND: The biology of the estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancers is heterogeneous even when they are categorized by their risk via genomics. Transcriptomic PGR expression reflects endocrine pathway activity and may provide complementary biological information within established GENE70-derived genomic-risk categories. Whether this molecular marker improves the b…

PubMed2026

Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment.

VKORC1 genetic variants are major determinants of interindividual variability in vitamin K antagonist (VKA) dose requirements and are incorporated into several pharmacogenetic dosing guidelines. The promoter variant rs9923231 is considered the clinically relevant marker for genotype-guided VKA dosing. However, the intronic variant rs9934438 is sometimes used as a surrogate marker because it is assumed to be in strong linkage disequilib…

PubMed2026

Molecular Design and Anticancer Activities of Small-Molecule BRAF Inhibitors: A Medicinal Chemistry Perspective.

BRAF is a cytoplasmic serine-threonine protein kinase that plays a critical role in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by mutation in human cancers. Many classes of B-Raf small molecule inhibitors have been identified. In this review, we will highlight typical BRAF inhibitors developed during these decades and provide a reference for the exploration of more potential BRAF inhibitors in the f…